Pfizer and Ranbaxy Settle Lipitor Patent Dispute

Pfizer (New York) and Ranbaxy Laboratories Ltd. (Gurgaon) say they have settled their patent dispute involving Pfizer’s Lipitor, the largest selling cholesterol-lowering drug worldwide with sales of $12.7 billion. The agreement provides Ranbaxy with a license to sell Atorvastatin, the generic version of Lipitor, in the U.S. starting November 30, 2011, and in Australia, Belgium, Canada, Germany, Italy, the Netherlands, and Sweden starting at various dates, the firms say. The agreement follows unconfirmed media reports earlier this month regarding the...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers